First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
Z Yang, Y Zhu, G Xiang, T Hua, J Ni… - Expert review of …, 2021 - Taylor & Francis
Objective: To assess the cost-effectiveness of atezolizumab in combination with carboplatin
plus nab-paclitaxel-based chemotherapy versus chemotherapy alone for first-line treatment …
plus nab-paclitaxel-based chemotherapy versus chemotherapy alone for first-line treatment …
Short-term association between ambient air pollution and lung cancer mortality
N Wang, K Mengersen, S Tong, M Kimlin, M Zhou… - Environmental …, 2019 - Elsevier
Rationale Long-term exposure to air pollution has been associated with increased lung
cancer incidence and mortality. However, the short-term association between air pollution …
cancer incidence and mortality. However, the short-term association between air pollution …
Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma
R Meng, X Zhang, T Zhou, M Luo… - Expert Review of …, 2022 - Taylor & Francis
Background Donafenib and lenvatinib are approved by China National Medical Products
Administration and recommended as first-line treatment of Metastatic Hepatocellular …
Administration and recommended as first-line treatment of Metastatic Hepatocellular …
[HTML][HTML] Cost-effectiveness of domestic PD-1 inhibitor camrelizumab combined with chemotherapy in the first-line treatment of advanced nonsquamous non–Small …
L Qiao, Z Zhou, X Zeng, C Tan - Frontiers in pharmacology, 2021 - frontiersin.org
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with
chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer …
chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer …
[HTML][HTML] First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: A network meta-analysis and cost …
S Kang, X Wang, Y Zhang, B Zhang, F Shang… - Frontiers in …, 2022 - frontiersin.org
ABSTRACT Background: Immune checkpoint inhibitors (ICIs) plus chemotherapy were
unlikely to be considered cost-effective compared with chemotherapy as the first-line …
unlikely to be considered cost-effective compared with chemotherapy as the first-line …
Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost …
K Tian, J Han, Z Wang, J Chen - Oral Oncology, 2022 - Elsevier
Objectives This study was aimed to evaluate the cost-effectiveness of the recently approved
first-line treatments, toripalimab or camrelizumab combined with gemcitabine plus cisplatin 2 …
first-line treatments, toripalimab or camrelizumab combined with gemcitabine plus cisplatin 2 …
[HTML][HTML] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - Scientific Reports, 2022 - nature.com
Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
[HTML][HTML] Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
Background This study aimed to evaluate the cost-effectiveness of camrelizumab versus
chemotherapy as second-line treatment for patients with advanced/metastatic esophageal …
chemotherapy as second-line treatment for patients with advanced/metastatic esophageal …
Probabilistic and dynamic molecule-disease interaction modeling for drug discovery
Drug discovery aims at finding promising drug molecules for treating target diseases.
Existing computational drug discovery methods mainly depend on molecule databases …
Existing computational drug discovery methods mainly depend on molecule databases …
[HTML][HTML] Cost-effectiveness of tucatinib in human epidermal growth factor receptor 2–positive metastatic breast cancer from the US and Chinese perspectives
Q Wu, W Liao, M Zhang, J Huang, P Zhang… - Frontiers in oncology, 2020 - frontiersin.org
Background: The clinical evaluation of HER2CLIMB trial showed a 21. 9-month median
overall survival with the triplet regimens of tucatinib, capecitabine, and trastuzumab (TXT) for …
overall survival with the triplet regimens of tucatinib, capecitabine, and trastuzumab (TXT) for …